EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
5.85
+0.04 (0.69%)
At close: May 12, 2025, 4:00 PM
5.86
+0.01 (0.17%)
Pre-market: May 13, 2025, 5:00 AM EDT
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for EyePoint Pharmaceuticals stock ranges from a low of $15 to a high of $33. The average price target of $24 forecasts a 310.26% increase in the stock price over the next year.
Price Target: $24.00 (+310.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 → $27 | Strong Buy | Maintains | $33 → $27 | +361.54% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +464.10% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +276.07% | Mar 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +464.10% | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +464.10% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
25.08M
from 43.27M
Decreased by -42.04%
Revenue Next Year
14.44M
from 25.08M
Decreased by -42.41%
EPS This Year
-2.80
from -2.32
EPS Next Year
-2.77
from -2.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 53.1M | 53.6M | 202.7M | ||
| Avg | 25.1M | 14.4M | 89.5M | ||
| Low | n/a | n/a | 38.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.8% | 113.5% | 1,303.0% | ||
| Avg | -42.0% | -42.4% | 519.9% | ||
| Low | - | - | 163.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.15 | -1.53 | -0.66 | ||
| Avg | -2.80 | -2.77 | -2.37 | ||
| Low | -3.08 | -3.64 | -3.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.